Søren Melsing
Chief Executive Officer Exocure
Søren Melsing Frederiksen is CEO of Exocure AB, leading the development and commercialization of exosome-based therapeutic platforms across drug delivery, inflammation, and oncology. He brings over 20 years of experience spanning R&D, product development, and commercialization, with senior leadership roles at Orifarm, Galenica, Aspen Pharma, and LEO Pharma.
Seminars
Thursday 24th September 2026
Understanding the Investment Landscape in Exosome Therapeutics & Evaluating the Risk Return of Clinical Validation & Scalable Platform Opportunity
9:00 am
- Identifying key value drivers from an investor perspective including clinical proof-ofconcept, regulatory clarity, and manufacturability at scale
- Differentiating platforms based on strength of biological rationale, delivery efficiency, and defensibility of intellectual property
- Assessing risk-adjusted return profiles across early-stage assets, focusing on translational milestones and partnering or exit opportunities
